Investigational eye treatment: Corneal collagen crosslinking research study

Teaneck, NJ – The Cornea and Laser Eye Institute, with Principal Investigator, Peter S.Hersh M.D., is conducting a research study to study the safety and effectiveness of cornealcollagen crosslinking (CXL) using Riboflavin/Dextran and Hypotonic Riboflavin inpatients with progressive keratoconus and corneal ectasia.

Keratoconus is a disease of the cornea, the clear front lens of the eye (like the crystal on awatch), that occurs in the overall population at a rate of about one in 2000. It usuallybegins in the teens and 20's and can worsen over time. It is often discovered when visioncannot be properly corrected with glasses. Keratoconus results in thinning of the cornealtissues. Consequently, the cornea bulges out of its smooth, clear, dome-like structure, andassumes a more conical and irregular configuration. Because of this change in shape, thecornea loses its ability to form a clear image in the eye and the patient's vision candecrease drastically. Treatments include specialty keratoconus contact lenses and cornealinlays. However, the keratoconus cornea can continue to bulge over time and somekeratoconus patients ultimately may require corneal transplantation to regain vision.

Corneal collagen crosslinking (CXL) using ultraviolet light combined with riboflavin(Vitamin B2) is an investigational procedure designed to strengthen the cornea and decrease theprogression of keratoconus. CXL is an investigational procedure and is not approved for use in the United States. However, here at the CLEI Center for Keratoconus, we are participating in a research study of CXL. The goal of the study is to assess the safety and efficacy of crosslinking for the treatment of keratoconus as well as corneal ectasia after LASIK. If successful, CXL may decrease progression of keratoconus and maintain the patient's vision over time.

During the crosslinking procedure, anesthesia drops are administered. The surfaceepithelial cells of the cornea are then removed and riboflavin drops are administered for30 minutes. The riboflavin acts both to enhance the crosslinking effect and to protect therest of the eye from the UV exposure.

The patient then looks at a UV emitting light for 30 minutes. At the conclusion of theprocedure, a soft contact lens bandage is applied. The contact lens is left in place toimprove healing for approximately 5 days and is then removed. Antibiotic and anti-inflammatorydrops are used for two weeks afterwards.

Source: The Cornea and Laser Eye Institute, P.A.